Dear members of the ESC Working Group on Atherosclerosis and Vascular Biology,
A new clinical trial on colchicine after myocardial infarction, recently presented at the AHA, has once more put the spotlight on targeting inflammation in cardiovascular prevention. Such clinical trials support that findings initially made in vascular biology studies were clinically applicable, and illustrate the importance of translational research in cardiology. Along the same inflammation theme, this newsletter will provide an update on macrophages – a key player in atherosclerosis.
Single cell sequencing is a novel powerful tool in atherosclerosis research. Do not miss our WG symposium on Single Cell Analysis in Atherosclerosis, arranged just before FCVB congress, on Thursday 23 April 2020 14-16h at the Semmelweis University in Budapest, Hungary. Look out for more information and registration. Hoping to meet many of you there!
On behalf of the Working Group nucleus,
Magnus Bäck
Chair WG Atherosclerosis and Vascular Biology
Publications
Our selection of recommended reading this month includes:
- Endothelial GLP-1 (Glucagon-Like Peptide 1) Receptor Mediates Cardiovascular Protection by Liraglutide In Mice With Experimental Arterial Hypertension. Arterioscler Thromb Vasc Biol. 2019 Nov 21:atv00006154569786230
- Extracellular vesicles in metabolic disease. Diabetologia. 2019 Dec;62(12):2179-2187
- Efficacy and Safety of Low-Dose Colchicine after Myocardial Infarction. N Engl J Med. 2019 Nov 16.
And make sure to read our Papers of the Month commented by Prof.dr. Menno P.J. de Winther:
Best wishes
Prof. Magnus Back, Chairperson
Our mission: To reduce the burden of cardiovascular disease.